Thalidomide-Dexamethasone for Multiple Myeloma

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Multiple Myeloma
Interventions
DRUG

Thalidomide

100 mg capsules by mouth daily each evening

DRUG

Dexamethasone

20 mg/m\^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.

Trial Locations (1)

77030

University of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER